Robert Christos Nelson·May 9Novo’s CagriSema “Disappointed.” The Trial Data Is Way Better Than the Market Thinks.Wall Street decided in twenty minutes that Novo Nordisk’s next weight loss drug had failed. They were reading the wrong number. Here’s what…
Branislav Ceperkovic·Apr 16Part 3: Will GLP-1 Drugs Replace Lifestyle Medicine?Or are we redefining what “lifestyle” actually means?
William Lloyd Garrison Center for Libertarian Advocacy Journalism·Feb 10Semaglutide: Artificial Shortage Is Novo Nordisk’s Business ModelIn early February, drug company Novo Nordisk sued telehealth company Hims & Hers.
Growth Stock Bets·Aug 24, 2025Why Hims Will Succeed Where All Telehealth Has Failed.When the pandemic started, Telehealth seemed as obvious a trend as virtual meetings. No one was interested in going anywhere near a…
